TABLE 1.
Characteristics of study population
|
All SOT (n = 4405) |
No bacterial foodborne infection (n = 4268) |
Bacterial foodborne infection (n = 137) |
|
|---|---|---|---|
| Age at enrollment, median (IQR) | 53 (41–61) | 54 (42–61) | 51 (37–60) |
| Sex (female), n (%) | 1599 (36.3%) | 1553 (36.4%) | 46 (33.6%) |
| Type of transplantation, n (%) | |||
| Kidney | 2467 (56.0%) | 2375 (55.7%) | 92 (67.2%) |
| Liver | 944 (21.4%) | 925 (21.7%) | 19 (13.9%) |
| Heart | 335 (7.6%) | 321 (7.5%) | 14 (10.2%) |
| Lung | 403 (9.2%) | 397 (9.3%) | 6 (4.4%) |
| Combined a | 212 (4.8%) | 207 (4.9%) | 5 (3.7%) |
| Other b | 44 (1.0%) | 43 (1.0%) | 1 (0.7%) |
| Living donor, n (%) | 1075 (24.4%) | 1028 (24.1%) | 47 (34.3%) |
| Re or second transplantation at enrollment, n (%) | 470 (10.7%) | 446 (13.3%) | 24 (17.5%) |
| Induction immunosuppression, n (%) | |||
| Basiliximab | 3093 (70.2%) | 3000 (70.3%) | 93 (67.9%) |
| Anti‐lymphocyte globulin | 1007 (22.9%) | 974 (22.8%) | 33 (24.1%) |
| Maintenance immunosuppression, c n (%) | |||
| Tacrolimus | 3269 (74.2%) | 3166 (74.2%) | 103 (75.2%) |
| Cyclosporin | 944 (21.4%) | 911 (21.3%) | 33 (24.1%) |
| Mycophenolate (MMF or MPA) | 3943 (89.5%) | 3812 (89.3%) | 131 (95.6%) |
| Azathioprine | 76 (1.7%) | 74 (1.7%) | 2 (1.5%) |
| mTOR inhibitors | 143 (3.3%) | 140 (3.3%) | 3 (2.2%) |
| Prednisone | 4005 (90.9%) | 3878 (91.0%) | 127 (92.7%) |
| TMP‐SMX prophylaxis, n (%) | 3880 (88.1%) | 3755 (88.0%) | 125 (91.2%) |
| Months of TMP‐SMX, median (IQR) | 6.1 (4.9–12.4) | 6.1 (4.9–12.4) | 6.3 (5.3–13.4) |
| Follow‐up in years, median (IQR) | 4.2 (1.9–7.0) | 4.2 (1.9–7.0) | 5.7 (3.8–7.9) |
| Outcome at end of follow‐up, n (%) | |||
| Lost to follow‐up | 46 (1.0%) | 44 (1.0%) | 2 (1.5%) |
| Patients with graft failure d , e | 452 (10.3%) | 441 (13.2%) | 11 (8.0%) |
| Death e | 538 (12.2%) | 529 (15.8%) | 9 (6.6%) |
| Death with functioning allograft | 444 (10.1%) | 435 (13.0%) | 9 (6.6%) |
Abbreviations: IQR, interquartile range; MMF, mycophenolate mofetil; MPA, mycophenolic acid; mTOR, mammalian target of rapamycin; SOT, solid organ transplant; TMP‐SMX, trimethoprim‐sulfamethoxasole.
Including kidney‐pancreas (93), kidney‐kidney (43), kidney‐liver (38), kidney‐islets (16), kidney‐heart (8), liver‐lung (4), pancreas‐small bowel (2) heart‐lung (1), kidney‐lung (1), islets‐liver (1), liver‐pancreas (1), kidney‐kidney‐pancreas (2), kidney‐islets‐liver (1), islets‐liver‐lung (1) transplant recipients.
Including islets (30), pancreas (13), and small bowel (1) transplant recipients.
Maintenance immunosuppression represent immunosuppression at day 30 after transplantation.
Including primary non‐function (50).
Death and graft failure occurred on the same day in 94 patients.